New combo pill aims to lower cholesterol in phase 3 trial

NCT ID NCT06955104

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 3 trial tested a combination of two drugs, JW0108 and C2407, in 145 adults with high cholesterol (dyslipidemia). The goal was to see if the combo lowers LDL ('bad') cholesterol more effectively and safely than placebo. Researchers measured changes in LDL levels from the start of the study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

JW0108 and C2407 (two drugs combined)

What this could lead to

If it works, this could offer a new combination treatment to help control high cholesterol and reduce heart disease risk.

What could go wrong

This is a completed Phase 3 trial, but results are not yet published. The combination may not be more effective than existing treatments, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea